To develop and evaluate severity-adjusted indicators of treatment timeliness and adequacy for inpatient care of first episode of HTV-related pneumocystis pneumonia, a retrospective cohort study (n -414) using medical record review was conducted in six California medical centers (1 January 1983-30 June 1987). Measures included patient baseline characteristics and complexity, process-of-care indicators (delay in treatment initiation and proportion of adequate treatment delivered), and overall survival of hosphalization and survival without respiratory failure. Logistic regression models of severity were developed among optimally treated patients and cross-validated. Exposure to medication with pneumocystis activity within 30 days prior to admission was protective. After controlling for pre-admission medication and severity, the average proportion of adequate pneumocystis medication delivered during the first 7 and 30 days were significant predictors of outcome hi all models. Delay hi treatment initiation, while not a statistically significant predictor, was associated with baseline severity. Summary measures of treatment adequacy show promise as process-of-care indicators.
INTRODUCTION
A number of studies have identified important variations in severity-adjusted institutional outcomes for HFVrelated pneumocystis pneumonia. Demographic characteristics, source of payment for care, institutional experience, access to diagnostic procedures such as bronchoscopy, and timely initiation of appropriate medication have been identified as factors associated with improved outcomes [1] [2] [3] [4] [5] [6] [7] [8] . Few studies, however, have convincingly demonstrated how specific processes of care explain severity-adjusted outcome differences.
Results of randomized controlled clinical trials have identified components of the process of medical care for pneumocystis pneumonia which could serve as qualityof-care indicators in settings of routine care. In particular, the timely initiation of appropriate medication used in adequate doses should be an important mediator of the observed outcomes of care after baseline prognostic differences are accounted for. As part of a comprehensive analysis of quality of care delivered to patients experiencing pneumocystis pneumonia as their AIDS-defining condition between 1983 and 1987 [9] , detailed medical record abstraction was undertaken to study treatment adequacy as a quality-of-care indicator predictive of important patient outcomes.
The complete study focused on the "episode of care" for individual patients [10] , including the pre-hospital interval of care and extending to 30 days after hospital admission. The principal study outcomes for the episode of care were overall and severe, respiratory, failure-free survival. Measures of baseline severity were identified through previous research and included: selected patient characteristics, indicators of both pulmonary severity and extrapulmonary dysfunction, and resource utilization associated with severity [11] [12] [13] [14] [15] [16] [17] [18] . To avoid possible confounding in the measurement of baseline severity of illness by early treatment effects [19] , the study design required that severity models be developed among patients who received at least adequate therapy for pneumocystis pneumonia during the first week of their hospitalization. Severity indices developed among adequately treated patients were then applied to the analysis study sample to examine the effects of process of care on outcomes after severity had been controlled. Definitions of adequate therapy were based on literature review and recommendations of a consensus panel of expert physicians [20] . The study period concluded prior to the widespread use of adjunctive corticosteroids in the treatment of pneumocystis pneumonia [21] .
In this paper, we report analyses pertaining to study patients whose "episode of care" for pneumocystis pneumonia began on the date of hospital admission, and examine outcomes and processes of care limited to the inpatient portion of the care episode. We describe: (1) the descriptive epidemiology of the analysis sample, process of care, and outcomes; (2) the development of severity models for both overall and severe-respiratoryfailure-free survival of the hospitalization; and (3) the estimation of effects of treatment timeliness and adequacy after controlling for baseline severity.
METHODS

Study sites, inclusion and exclusion criteria
A retrospective review of inpatient and outpatient medical records was conducted in six California medical centers. Study sites were selected to provide a reasonable geographic distribution in California and variation in teaching status and bed capacity. All centers had more than 400 beds, 2 were major teaching hospitals, 1 an HMO facility and 1 a county hospital. Within each medical center, administrative databases were searched to identify adult (> 18 years) patient encounters associated with eligible ICD-9-CM diagnostic codes during the study period (1 January 1983 to 30 June 1987). Records were excluded from the study if initial medical record review indicated a prior diagnosis of AIDS by the 1985 surveillance case definition [22] , pneumocystis pneumonia diagnosed more than 30 days prior to the marker admission, or inoperable cancer. The current analysis is restricted to those patients whose episode of care for pneumocystis pneumonia began on the date of hospital admission and who were definitively diagnosed. Medical records were abstracted by 11 registered nurses who were intensively trained by study personnel.
Measures
Data elements corresponding to indicators of baseline severity and co-morbidity, process of medical care and outcomes were identified and specified as described in detail elsewhere [10] . Two outcomes were examined: (1) overall survival of the hospitalization; and (2) survival of the hospitalization free of severe respiratory failure. Severe respiratory failure was operationally defined as endotracheal intubation for >24 hours. Patient characteristics examined included: sex, age, race/ethnicity, HIV transmission mode, admission source (emcrgency/nohemergency), type of insurance, year of admission and whether medications active against pneumocystis were taken within 30 days prior to admission. Indicators of pulmonary severity included: number of respiratory symptoms, chest roentgenographic abnormality [18] , respiratory rate [18] , heart rate, serum lactate dehydrogenase (LDH) [11, 15] , hypoxemia ratio [23] , use of supplemental oxygen and early intensive care (ICU) use. Measures of co-morbidity included: serum albumin, absolute neutropbil count, total lymphocyte count [16, 17] , white blood cell count, hemoglobin, platelet estimate, blood urea nitrogen, serum creatinine, venous bicarbonate, serum sodium, serum bilirubin, body mass index [17] and diarrhea on admission. Severity and comorbidity indicators were recorded as the most severe or abnormal values documented during the first 2 hospital days. Among process-of-care measures examined, timeliness and adequacy of pneumocystis-specific antimicrobial therapy were hypothesized to have a direct causal relationship to principal study outcomes. Appropriate pneumocystis medications were defined as parenteral pentamidine isothionate, trimethoprim/sulfamethoxazole, or dapsone plus trimethoprim. Doses were transformed to a common metric of milligrams/kilogram body weight/24 hour period. At each outpatient visit and on each day of hospitalization up to 30 days, abstractors recorded the presence or absence of therapy with these drugs and characterized the dosage adequacy, using criteria recommended by" the consensus panel of expert physicians, based on the standard of practice prevailing at the time covered by the study. "Initial medical recognition" was defined as the date of the first notation in the medical record of symptoms, signs, laboratory results, or orders that were subsequently shown, in the judgment of a physician over-reader blinded to outcome, to be associated with an episode of pneumocystis pneumonia. A random sub-sample of records was over-read by a second physician to assess reliability. Timeliness of pneumocystis therapy was measured as the length in days of the pre-treatment interval: the number of elapsed days from "initial medical recognition" to the first date at which administration of pneumocystis therapy was noted in the medical record. For patients who had taken agents with pneumocystis treatment activity in the 30 days prior to admission (either for prophylaxis or for another unrelated treatment indication), this interval was set equal to zero. Pneumocystis treatment adequacy was measured by 2 indicators: 7-day and 30-day average treatment adequacy (ATA-7 and ATA-30). Construction of these 2 treatment adequacy measures was a 2-step process. First, for each potential treatment day following "initial medical recognition", pneumocystis treatment adequacy was calculated as a percentage of the minimum adequate recommended daily dose for a given drug therapy. Second, for each patient, the daily percentages of treatment adequacy were averaged over the number of "eligible days" during the first 7 and first 30 days of hospitalization. If a patient succumbed or was discharged prior to completing the respective 7-or 30-day interval, treatment adequacy was averaged over the eligible days during which the patient was hospitalized. In models predicting the combined outcome of sevcrerespiratory-failure-free survival, eligible days for calculation of ATA-7 and ATA-30 were further restricted to Treatment adequacy for HIV-related pneumocystis pneumonia 351 those days preceding the date of intubation for those patients experiencing the study definition of severe respiratory failure.
Analysis
Univariate distributions of study measures and bivariate associations with outcomes were examined using contingency table methods. Bivariate results are presented as percentages with specified outcomes by patient characteristic. The primary analytic method was logistic regression for dichotomous outcomes. Although survival analysis techniques would have been more appropriate, information on survival status following hospital discharge was fragmentary, even for ascertainment of 30-day vital status. Because censoring on hospital discharge was not unrelated to study outcomes, lifetable estimates of the study outcomes would have been seriously biased. Two severity models were developed using multiple logistic regression (STATA, version 5.0) to estimate the independent value of markers of severity and comorbidity for predicting (1) the odds of overall survival of the hospitalization and (2) the odds of survival of the hospitalization without experiencing severe respiratory failure. Resource-utilization indicators of baseline severity (ICU use and intubation during hospital days 1 or 2) were not candidates to enter the severity models. Severity models were first developed in a "derivation set" designated by conditioning on optimal treatment during the first week of hospitalization. The derivation set or optimal-treatment sample was specified as those patients for whom "initial medical recognition" occurred on the day of hospital admission, who had not taken medication with pneumocystis treatment activity in the 30 days before admission, and who were documented to have received an average of more than 80% of a therapeutically adequate dosage of appropriate pneumocystis therapy during the first week in the hospital up to: (1) the date of discharge (for the overall survival prediction model), or (2) the date of intubation lasting more than 24 hours, or the date of death (for the model predicting the combined outcome). A common set of predictors was chosen to model severity and co-morbidity for both outcomes (overall survival and survival free of severe respiratory failure). The choice of predictors was based on the results of stepwise regression modeling supplemented by results of previous research. The final severity models included hypoxemia ratio and serum lactate dehydrogenase (LDH) because of the prognostic importance of these variables in previous studies of pneumocystis pneumonia [11, [15] [16] [17] . Severity and co-morbidity parameter estimates derived in the optimal treatment sample were applied to the "test set" of remaining patients. Confidence intervals for adjusted odds ratios were based on bias-corrected bootstrap estimates of the standard error of odds ratios [24] . Severity model calibration and discrimination were assessed by the Hosmer-Lemeshow goodness-of-fit statistic and measurement of area under the ROC curve, respectively [25, 26] . Next, logistic severity scores based on the crossvalidated severity models were calculated as the predicted log odds of the 2 outcomes and entered into subsequent models examining separately the severity-adjusted effects on outcome of the 3 process of care indicators: pretreatment interval, ATA-7, and ATA-30. Confidence intervals reported in models estimating process-of-care effects were based on robust estimation of standard errors adjusted for clustering within hospitals [27] . In estimating these process-of-care effects, study site and treatment with pneumocystis active medications within 30 days prior to admission were examined as potential confounders of treatment effects. Two-way interactions between the process-of-care measures and both severity score and selected baseline characteristics were examined.
RESULTS
Records of 1048 admissions met initial age and ICD-9-CM eligibility criteria. Nine percent (n = 93) of the records sampled could not be located. Of the 955 records located, 331 (35%) were excluded from the study by criteria applied by abstractors in the field, such as a prior episode of pneumocystis pneumonia or AIDS diagnosis. An additional 78 (8%) were excluded after abstraction because over-reading physicians judged that a suspected but unconfirmed diagnosis of pneumocystis pneumonia was not supported by the patient's response to appropriate therapy. Thus 546 patients met overall study entry criteria across the six medical centers, of whom 515 were definitively and 31 (6%) presumptively diagnosed. Of these 546 patients, 414 (75.8%) began their episode of care for pneumocystis pneumonia on the date of hospital admission-and were definitively diagnosed. These 414 patients comprise the analysis sample. The proportion of originally sampled records remaining in the analysis sample varied from 24% to 61%, averaging 52% across all 6 study sites. Nearly all patients were males; although 29% were either black or Hispanic, the typical patient was a white non-Hispanic gay or bisexual man. There were 99 in-hospital deaths and 114 occurrences of the combined outcome of death or severe respiratory failure. The overall in-hospital mortality rate for these firstepisode pneumocystis pneumonia patients was 24% (range 10%-29%, p-value for difference across sites 0.076). By site, mortality proportions and sample sizes were: (1) 28.6% (n = 49), (2 and 6) 10.3% (n = 39), (3) 18. 1% (n = 83), (4) 22.2% (n = 83), (5) 22.2% (n = 54), and 28.6% (n = 189). The median length of stay was 16 days (interquartile range: 12-22), during which time 27% of all patients received intensive care and 20% were intubated, 18% for more than 24 hours, thereby meeting the study definition of severe respiratory failure.
Among patients who died in the hospital, 10% of the deaths occurred by the 6th hospital day, 50% by the 15th day, and 90% by the 27th hospital day. A single patient admitted with pneumocystis pneumonia remained hospi-talized and succumbed on the 126th hospital day. Among patients developing the combined outcome of either death or severe respiratory failure, 10% of the outcomes occured by the 2nd day, 50% the 6th day, and 90% by the 18th day. Because of the bias incurred by non-random censoring of observations on hospital discharge, survival analysis techniques were not used as the primary analytic method. However, Figure 1 is presented to illustrate the temporal pattern of mortality events. Agreement among physician over-readers in assigning the date of "initial medical recognition" was 80%; disagreements were resolved by review of over-reader notes and worksheets. The length of pre-treatment interval was Odays in 193 (46.6%), 1 day in 157 (37.9%), 2 days in 26 (6.3%), and 3 or more days in 38 (9.2%). The longest pre-treatment interval was 16 days following admission. The average pre-treatment interval across medical centers ranged from 0.3 days to 1.3 days.
Twenty-five patients (6.0%) received sub-therapeutic doses of medications with pneumocystis treatment activity during the 30 days prior to admission. By medical center, prevalence of prior treatment varied from 0-12.5%. By study definition, all 25 of these patients were assigned a pre-treatment interval of zero days. Of the 25, 21 (84%) began therapeutic doses for pneumocystis treatment on day 1 or 2 of hospitalization, 2 (8%) on day 3, and 1 each on days 5 and 7, respectively.
Pneumocystis treatment adequacy, measured as ATA-7 and ATA-30, was high but varied considerably. Median values (interquartile range) were 0.81 (0.67-0.86) and 0.77 (0.65-0.87), respectively. Trimethoprim/sulfamethoxazole was the first pneumocystis medication administered in the hospital for 84.4% of patients, parenteral pentamidine for 15.5%; two patients were given both, and two received neither. Thirty-eight patients (9.2%) were treated with systemic corticosteroids; of these, only 14 were prescribed systemic corticosteroids in the first four days of hospitalization, suggesting that adjunctive (as opposed to rescue) use was uncommon. This conclusion is further supported by the finding of a strikingly higher rate of death or severe respiratory failure among patients treated with steroids (53% vs. 21%, p<0.0001).
Do-not-attempt-resuscitation (DNAR) orders were written on 89 (22%) patients. The prevalence of DNAR orders varied by hospital from 11 to 33%. Of the DNAR orders, 19% were written on either the first or second hospital day. Those with early DNAR orders (days 1 or 2) were less likely to die than those with DNAR orders written later (35% vs. 65% mortality, p = 0.03).
Bivariate analyses showed that in-hospital mortality was significantly related to several patient characteristics, including ethnicity, insurance provider, emergency admission, hospital resource use and the use of pneumocystis medications within 30 days before admission. However, there was no significant relationship between survival and gender, HIV transmission risk factor, or year of hospitalization. Table 1 shows bivariate relationships between survival of hospitalization and indicators of severity of the pulmonary process. Except for number of respiratory symptoms, all are significantly predictive of outcome when considered individually. Table 2 displays the same bivariate results for extrapulmonary co-morbidity measures. Significant relationships were found between probability of survival and serum albumin, absolute neutrophil count, total lymphocyte count, white blood cell count, blood urea nitrogen (BUN), venous bicarbonate, diarrhea and thrombocytopenia.
In unadjusted analysis, evaluating pre-treatment interval in its original metric (number of days), there was no differerence in median duration of pretreatment interval by outcome status for either the overall hospitalization survival or combined outcomes. In bivariate analysis, the median proportion of treatment adequacy did not vary significantly across groups for the survival endpoint. For ATA-7, median values were 0.81 for survivors vs. 0.81 for non-survivors (p = 0.75). However for the combined outcome, in unadjusted analyses there were significant differences in treatment adequacy. For ATA-7, median values were 0.82 for those without the outcome and 0.67 for those who experienced the outcome (p< 0.0001). The corresponding median values for ATA-30 were 0.82 vs. 0.69 (p= -0.0002), respectively.
Severity and co-morbidity variables that had signifi- cant predictive value in bivariate models of survival were entered into stepwise logistic regression models of survival and of severe-respiratory-failure-free survival in patients in our optimal treatment samples. Based on these stepwise models and results of previous research, 6 variables were selected for inclusion as severity and comorbidity adjusters for the later estimation of treatment effects: respiration rate, heart rate, serum lactate dehydrogenase (LDH), BUN, plasma hemoglobin, and hypoxemia ratio. Separate severity models were estimated for prediction of overall survival of hospitalization (Table 3 ) and for survival free of severe respiratory failure ( Table 4 ). Indices of model discrimination (ROC area) and calibration (Hosmer-Lemeshow chi square) for both optimal treatment and cross-validation samples are presented in the tables. Cross-validated models showed very little decrement in discrimination. The HosmerLemeshow chi square statistics, however, suggested poor calibration in the cross-validation samples. The poorly calibrated strata were predominantly those with predicted low probabilities of favorable outcome, more patients experiencing favorable outcomes than predicted by the models.
Bivariate analysis had shown a striking and unanticipated protective association of the use of medication with pneumocystis activity within 30 days prior to hospital admission (96% vs. 74.7% survival, p = 0.016). Although prior treatment varied by site (from 2% to 10%), a protective effect against death or severe respiratory failure was present in all sites and persisted after adjusting for site (adjusted odds ratio for survival free of respiratory failure 11.15, p = 0.019). Prior treatment could not be viewed either as a severity measure or as a component of process of care after admission. It was therefore included as a control variable in models of postadmission severity-adjusted process-of-care effects. Tables 5 and 6 present results from logistic regression models of study outcomes, examining process-of-care (pre-treatment interval, ATA-7, and ATA-30) effects adjusted for severity of illness and pre-admission pneumocystis medication use. In each model, odds ratios greater than 1 indicate a higher probability of the more favorable outcome. Treatment adequacy measures (ATA-7 and ATA-30) were rescaled by converting to a 0-100 percentage scale and then dividing by 10 to reflect 10% increments in treatment adequacy. In all models, the control variables (severity index and pre-admission pneumocystis medication) maintain significant and expected relationships with outcomes. In estimating models for the adjusted effects of pre-treatment interval on patient outcomes, the hypothesized effect of better outcomes with shorter pre-treatment intervals was not fully supported. Bivariate analyses suggested a complex relationship between pre-treatment interval and the outcome measures.
Specifically, for pre-treatment intervals of 0-2 days in duration, unfavorable outcome rates increased daily and monotonically from 23.3% to 42.3% for the combined "Confidence intervals based on bias-corrected bootstrap estimation of standard error of adjusted odds ratios calculated on the optimal treatment sample.
Model discrimination as ROC area: 0.84 (optimal treatment sample) and 0.73 (validation sample).
Model calibration as Hosmer-Lemeshow chi square: 0.92, p"*0.92 (optimal treatment sample) and 33.99, p<0.0001 (validation sample). •Confidence intervals based on bias-corrected bootstrap estimation of standard error of adjusted odds ratios calculated on the optimal treatment sample.
Model discrimination as ROC area; 0.84 (optimal treatment sample) and 0.76 (validation sample).
Model calibration as Hosmer-Lemeshow chi square: 3.66, p = 0.45 (optimal treatment sample) and 136.06, p<0.0001 (validation sample). outcome and from 20.2% to 38.5% for the survival outcome; however, this apparent trend was not sustained for either outcome measure for pre-treatment intervals of 3 days or longer. To explore further what might explain the loss of trend, severity scores were examined by pretreatment interval (categorized as 0,1,2, >3 days). Mean severity scores did not differ among patients with pretreatment intervals corresponding to 0, 1 or 2 days. However, the mean severity scores of patients with pretreatment intervals greater than or equal to 3 days was 0.6 logits less severe than the average severity of those with pre-treatment intervals less than 3 days (p = 0.02). In addition, the mean hypoxemia ratio for the same group was significantly higher than the mean of all other categories combined (360 vs. 298, p = 0.004), suggesting less pulmonary severity among those with prolonged pretreatment intervals. Logistic regression models including a two-way interaction between severity and pre-treatment interval were suggestive of heterogeneity of effect in predicting both outcomes (interaction p = 0.22 for the combined outcome model and p = 0.28 for the survival model).
For the 2 measures of pneumocystis pneumonia treatment adequacy (ATA-7 and ATA-30), the hypothesized relationships with outcome measures were strongly supported in logistic models adjusting for severity and pre-admission pneumocystis medication. For each 10% increase in treatment adequacy during the first 7 eligible hospital days (ATA-7), the odds of survival increased 0.13-fold. The effect of ATA-7 was more dramatic for the combined outcome: 0.28-fold better odds for each 10% increase in treatment adequacy. For both ATA-7 and ATA-30, the magnitude of detected treatment effect was greater in predicting the combined outcome than in predicting overall survival. To explore whether the effects of the treatment adequacy measures were modified by baseline severity, two-way interaction terms for treatment adequacy and severity were included in the main effects models presented in Tables 5 and 6 . All four severity-by-treatment adequacy interaction models suggested some modification of treatment effects by severity. In each case, the sign of the interaction term coefficients was negative. Thus, for a given value of the treatment adequacy measures, higher severity was predictive of a smaller benefit from treatment.
Finally, to assess whether differences in severity and care among the hospitals were adequately accounted for by the severity and treatment measures developed, logistic models were examined including severity, treatment adequacy measures, and hospital code. The hospital effect was no longer detectable in the prediction of either overall survival or the combined outcome DISCUSSION Developing outcome-oriented measures of treatment adequacy for pneumocystis pneumonia is a complex task.
We hypothesized that both timing and dose adequacy would be predictive of outcomes after adjustment for baseline severity. But how does one measure these properties of treatment? When and how should severity be ascertained? When does the clock start ticking for the measurement of treatment delay? What review criteria identify treatment initiation? Over how long a period should dose adequacy be assessed -the first week, the entire treatment period :-until an outcome occurs? In developing the measures presented in this paper, we were guided by previous work [19] and by the observed characteristics of actual treatment episodes and medical records.
Previous studies of quality of care in pneumocystis pneumonia have focused on hospital care, ignoring preadmission care that may determine severity of illness when admission becomes necessary. This truncation of the episode of care may over-adjust for severity differences between centers, excusing poor outcomes on the basis of severity that itself may represent poor antecedent care. Our study attempted to examine the entire episode of care by assigning a date of "initial medical recognition" to each patient, using the method of implicit medical record review [28] . Two problems, however, were immediately evident with this approach: (1) severity measures could rarely be ascertained at the time of "initial medical recognition" if this occurred in the outpatient setting, and (2) documentation of treatment detail was fragmentary in available outpatient records. Because of the first consideration, we elected to base severity measurement on hospital admission values and to develop severity models in those optimally treated patients who received no treatment with pneumocystis medications within 30 days before admission. Treatment effects were then estimated in a restricted sample (n = 414) of our orginally eligible patients (n = 546), including only those confirmed cases of pneumocystis pneumonia whose "initial medical recognition" occurred on the day of hospital admission.
The timing and conditions of severity measurement are potentially important in the unbiased assessment of treatment effects. Therapies, both antecedent and subsequent to severity measurement, may be confounded with severity estimates. Confounding, or mixing of effects, may distort severity effects if both of two conditions are met in a given dataset: (1) a potentially confounding treatment variable is associated with severity, and (2) the potential confounder is an independent predictor of the outcome [29] . In bivariate analyses, we found that prior treatment, dose adequacy and, to some extent, pre-treatment interval were each predictive of outcome. However, the degree of association between severity and both prior treatment and our process of care measures was small and inconsistent. If severe episodes are treated differently from others, failure to develop severity models among homogeneously treated patient groups may compromise an investigator's ability to detect treatment effects [19] .
Summary process-of-care measures may also be confounded with post-baseline changes in severity of illness if the period of summarized treatment is extended. In our data, it is likely that the magnitude of treatment effect estimated by the 30-day average treatment adequacy measure (ATA-30) was diminished compared to the same measure averaged over a briefer period (ATA-7) because of post-baseline changes in patient complexity. In addition, analysis of the combined endpoint facilitated detection of drug-treatment effects that might have been obscured by more powerful determinants of outcome subsequent to onset of respiratory failure.
Several limitations of our study merit comment. First, in estimating treatment adequacy, we treated all of the then standard treatments as equivalent, a judgment based on consensus panel recommendations and the objectives of the study. Second, although it was reasonable to exclude use of corticosteroids as an indicator of treatment adequacy at the time of our study, the subsequent demonstration of efficacy of "adjunctive corticosteroids" for moderate and severe pneumocystis pneumonia would lead to the inclusion in studies of contemporary datasets measures of corticosteroid use and timing with respect to "initial medical recognition." Third, by limiting the study to patients with little comorbidity and newly diagnosed AIDS, we hoped to select a study population that should receive aggressive treatment. If the study population included many patients who declined life-prolonging therapy or for whom such measures were judged "futile", interpretation of treatment adequacy measures would be ambiguous. Fourth, our inability to stage severity concurrently with the date of initial medical recognition in patients recognized prior to admission, precluded our ability to estimate treatment effects for these patients in an unbiased manner. Unfortunately, the limited availability of outpatient records and fragmentary documentation of severity and treatment indicators in available records, make the analysis of a complete episode of care problematic. In the current era, in which most pneumocystis care is delivered on an ambulatory basis, improvements in medical record technologies and documentation are essential if quality of care for entire illness episodes is to be evaluated. Fifth, because post-discharge vital status at a fixed time point following admission was incomplete and censoring on discharge was non-random, use of survival analytic techniques was problematic. Although we could not evaluate our treatment-adequacy measures as time-dependent variables, we believe thai both ATA-7 and ATA-30 were conservatively constructed. That is, adequately treated patients who developed outcomes prior to the end day of a treatment-summary measure (either day 7 or day 30) were credited with full treatment adequacy on the summary measure averaged over the number of eligible days before the outcome occured. The effect of adequately treated early-mortality patients would be to diminish the detectability of a treatment effect for the summary measure. Lastly, the general-izability of our results even to the inpatient setting may be limited by modifications in treatment practices,, including use of potent antiretroviral agents that may modify treatment effects and prognosis of acute opportunistic infections.
Summary measures of the average proportion of adequate therapy delivered to patients with initial episodes of pneumocystis pneumonia show promise as evaluable process-of-care indicators. Timeliness of therapy initiation, as measured by the duration of the pretreatment interval, while appearing at face value to be a reasonable quality indicator, seems difficult to validate, partly because of an association between delayed treatment and IOWCT severity. The "protective" effect of preadmission exposure to medications with pneumocystis treatment activity, unanticipated but consistent with a recent report [30] , may be an important determinant of patient outcomes, occurring prior to and independently of the establishment of baseline severity of illness. Measures of treatment timeliness and adequacy may be useful quality-of-care indicators for other complications of HTV infection.
